Latest Conference Articles

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

Take our latest 5-question quiz based on the recommended strategies of laboratory-based diagnosis of epidermolysis bullosa.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

A recap of the questions and top comments from our March 04, 2024, pre-AAD LinkedIn Chat highlighting the American Academy of Dermatology's 2024 annual meeting.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.

Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

Marinkovich discusses how the investigative cell-based graft therapy may serve a key role in the emerging DEB treatment paradigm.

In recognition of the Pre-AAD 2024 meeting, take our quiz based on Society for Pediatric Dermatology resources.

Lio shares 3 aspects of pain management that dermatologists can consider to improve the experience of procedures for patients.

Joyce Teng, MD, PhD, reviews a pair of recently approved agents for DEB—as well as a cell therapy awaiting FDA decision this year.